On-screen computerized decision support alert for Pulmonary Embolism

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pulmonary Embolism+4 More
On-screen computerized decision support alert - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether or not an electronic health record alert will increase echocardiographic screening for CTEPH and the diagnosis of CTEPH in patients with prior pulmonary embolism and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms.

Eligible Conditions
  • Pulmonary Embolism
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 3 Months

3 Months
Frequency of CTEPH diagnosis at three months.
Frequency of echocardiographic screening for CTEPH in patients with prior PE and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms at 3 months following randomization.

Trial Safety

Trial Design

2 Treatment Groups

No Alert
1 of 2
Alert
1 of 2

Active Control

Experimental Treatment

400 Total Participants · 2 Treatment Groups

Primary Treatment: On-screen computerized decision support alert · No Placebo Group · N/A

Alert
Behavioral
Experimental Group · 1 Intervention: On-screen computerized decision support alert · Intervention Types: Behavioral
No AlertNoIntervention Group · 1 Intervention: No Alert · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months

Who is running the clinical trial?

BayerIndustry Sponsor
2,142 Previous Clinical Trials
23,797,566 Total Patients Enrolled
21 Trials studying Pulmonary Embolism
1,076,101 Patients Enrolled for Pulmonary Embolism
Brigham and Women's HospitalLead Sponsor
1,472 Previous Clinical Trials
9,734,865 Total Patients Enrolled
20 Trials studying Pulmonary Embolism
811,067 Patients Enrolled for Pulmonary Embolism
Gregory Piazza, MD, MSPrincipal InvestigatorBWH
3 Previous Clinical Trials
10,410 Total Patients Enrolled
2 Trials studying Pulmonary Embolism
10,010 Patients Enrolled for Pulmonary Embolism

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are at least 18 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.